Security Snapshot

Aldeyra Therapeutics, Inc. - Common Stock, $0.001 par value per share (ALDX) Institutional Ownership

CUSIP: 01438T106

13F Institutional Holders and Ownership History from Q2 2014 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

44

Shares (Excl. Options)

9.85MFull value: 9,848,134 · shares · 30 Sep 2026

Price

$1.23

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, $0.001 par value per share
Symbol
ALDX on Nasdaq
All holders as of 30 Sep 2026
Q3 2026
Total 13F shares
9,848,134
Latest holder snapshot 5 signals
Total 13F value
$12,109,567
Portfolio coverage rank
0%
Share change
-923,569
Value change
-$1,442,379
Number of holders
44
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
60,596,036
SEC-reported price per share
$0.90
Insider filing price
$0.90
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • ALDX - Aldeyra Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 01438T106.
  • 44 institutions reported positions in Q3 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 107 to 44 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $77.75MFull value: $77,746,279 · USD · 30 Jun 2026
    to
    $12.11MFull value: $12,109,567 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 44 institutions filings for Q3 2026.

Open SEC evidence

Security key

01438T106

13F reference period

Q3 2026

13F holders

44

13D/G owners

3

CIK / CUSIP context first

Open Q3 2026 holders ALDX full holder history Aldeyra Therapeutics, Inc. SEC filings Aldeyra Therapeutics, Inc. company facts Aldeyra Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
3
Security
ALDX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BARCLAYS PLC 5.5% $2,979,528 3,310,587 Barclays PLC 30 Sep 2026
BlackRock, Inc. 1.7% $2,227,477 1,045,764 BlackRock, Inc. 30 Jun 2026
AQR CAPITAL MANAGEMENT LLC 1.1% -85% $605,354 -$2,771,048 672,616 -82% AQR Capital Management, LLC 30 Sep 2026
As of 30 Sep 2026, 44 institutional investors reported holding
9.85MFull value: 9,848,134 · shares · 30 Sep 2026
shares of Aldeyra Therapeutics, Inc. - Common Stock, $0.001 par value per share (ALDX). This represents 16% of the company’s total
60.6MFull value: 60,596,036 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
16%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD CAPITAL MANAGEMENT LLC 3.9% 2,392,805 +1.3% 0% $2,943,150
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 2.1% 1,287,331 +206% 0% $1,583,417
MARSHALL WACE, LLP 2.1% 1,251,681 -17% 0% $1,539,569
VANGUARD PORTFOLIO MANAGEMENT LLC 1.3% 807,326 +1.6% 0% $993,011
RENAISSANCE TECHNOLOGIES LLC 1.1% 660,336 -25% 0% $812,213
GEODE CAPITAL MANAGEMENT, LLC 1% 622,399 +4.4% 0% $765,883
MORGAN STANLEY 0.95% 575,791 -5.3% 0% $708,223
Connor, Clark & Lunn Investment Management Ltd. 0.77% 465,905 +202% 0% $573,063
VANGUARD FIDUCIARY TRUST CO 0.56% 339,155 +14% 0% $417,161
WOODSTOCK CORP 0.4% 242,756 0% 0.02% $298,590
STATE STREET CORP 0.36% 218,574 -6.5% 0% $268,846
DIMENSIONAL FUND ADVISORS LP 0.35% 209,969 -60% 0% $258,581
Invesco Ltd. 0.3% 184,238 +15% 0% $226,613
Qube Research & Technologies Ltd 0.2% 120,067 -89% 0% $147,682
AXQ CAPITAL, LP 0.09% 53,970 0.01% $66,383
Savant Capital, LLC 0.08% 47,646 0% $58,606
MACKENZIE FINANCIAL CORP 0.06% 37,632 0% $46,287
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC 0.06% 37,250 +1.4% 0% $48,053
CAPTRUST FINANCIAL ADVISORS 0.06% 36,202 -30% 0% $44,528
Mariner, LLC 0.06% 34,505 -62% 0% $42,441
Providence Wealth Advisors, LLC 0.04% 25,000 0% 0.02% $29,250
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC 0.04% 23,145 -51% 0% $21,935
Hikari Power Ltd 0.03% 20,020 0% 0.01% $25,000
Vanguard Global Advisers, LLC 0.03% 17,687 0% 0% $21,755
LETKO, BROSSEAU & ASSOCIATES INC 0.03% 17,300 0% 0% $21,279

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
50
Headline period
Q3 2026
Rows shown
1-25 of 50
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 9,848,134 $12,109,567 -$1,442,379 $1.23 44
2026 Q2 36,524,398 $77,746,279 -$758,348 $2.13 107
2026 Q1 37,269,714 $62,981,538 -$20,444,263 $1.69 127
2025 Q4 38,964,894 $201,775,126 -$2,038,386 $5.18 135
2025 Q3 39,091,752 $204,002,195 +$26,942,734 $5.22 129
2025 Q2 34,234,495 $131,165,420 -$14,803,182 $3.83 121
2025 Q1 37,522,553 $215,581,662 +$3,357,660 $5.75 124
2024 Q4 37,181,780 $185,566,183 +$2,534,433 $4.99 117
2024 Q3 36,411,204 $196,355,871 +$6,362,230 $5.39 111
2024 Q2 35,332,656 $116,899,840 -$329,270 $3.31 103
2024 Q1 35,411,236 $115,798,928 +$808,753 $3.27 101
2023 Q4 35,121,957 $123,276,317 -$16,780,776 $3.51 103
2023 Q3 37,775,090 $252,308,601 -$9,900,512 $6.68 120
2023 Q2 39,037,773 $327,514,881 +$24,184,461 $8.39 119
2023 Q1 35,585,837 $353,348,951 +$15,344,761 $9.93 107
2022 Q4 34,171,691 $237,833,495 -$18,830,170 $6.96 93
2022 Q3 36,966,565 $197,399,795 +$1,459,079 $5.34 85
2022 Q2 36,943,694 $147,408,805 -$7,357,330 $3.99 88
2022 Q1 38,636,557 $171,807,935 +$10,287,580 $4.44 102
2021 Q4 36,272,402 $145,130,796 -$44,887,818 $4.00 110
2021 Q3 39,720,964 $348,695,759 -$60,891,971 $8.78 114
2021 Q2 45,258,901 $512,794,552 +$153,473,538 $11.33 130
2021 Q1 31,692,851 $376,513,639 +$122,609,589 $11.88 107
2020 Q4 22,091,649 $151,541,784 -$10,169,396 $6.86 95
2020 Q3 23,807,765 $176,308,405 +$68,333,848 $7.41 84
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .